secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAge Labs, Inc. (BIOA)
CIK:        0001709941
Form:       8-K
Filed at:   2025-06-04T23:59:59+00:00
Accession:  0000950170-25-081409
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAge provides NLRP3 & APJ program timeline updates in corporate presentation
------------------------------------------------------------------------------

- NLRP3 program: IND submission and Phase 1 SAD/MAD initiation planned for mid-2025; initial SAD data expected by end of 2025.
- Full Phase 1 SAD/MAD data for NLRP3 program anticipated in mid-2026.
- Obesity proof-of-concept data for NLRP3 program expected in second half of 2026.
- APJ agonist program (oral and parenteral) expects IND submission by end of 2026.
- Company continues to advance both programs, with no financial guidance or data results provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1709941/000095017025081409/0000950170-25-081409-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1709941/000095017025081409/bioa-20250604.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-081409

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer